Bicalutamide and spironolactone are being compared for their effectiveness and safety in treating female pattern hair loss. The conversation seeks advice on which is better to use.
The conversation discusses hair regrowth treatments, specifically using finasteride, minoxidil, and microneedling with the Derminator. Users report significant improvements, especially after adding microneedling to their routine.
The conversation discusses whether someone with a naturally large forehead and widow's peak can get a hair transplant and start finasteride early. It also mentions a surgery to lower the hairline as an alternative.
The user experienced hair regrowth using 0.5mg oral finasteride and the iRestore laser cap every other day, with reduced shedding. They also take collagen peptides and Nutrafol vitamins, though they are unsure of the latter's effectiveness.
Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.
Hair follicles can be dormant and potentially revived with treatments like finasteride and minoxidil, but irreversible loss occurs if certain structures are destroyed. Early intervention is more effective, and additional methods like microneedling may help.
A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.
The user experienced a sudden decrease in hair density after starting alfatradiol while already using finasteride. Another user mentioned that initial shedding can occur with hair loss treatments, but it may not last long.
A user diagnosed with Alopecia Areata started using Litfulo (ritlecitinib), kenalog shots, and mometasone furoate 0.1%. They shaved their head and are seeking others' experiences with Litfulo.
User fought hair loss with Derminator microneedling, topical and oral minoxidil, and a 2000 FUE hair transplant. Derminator was a game changer, preventing further loss.
OP is experiencing significant hair loss despite GFC and PRP treatments and has abnormal lab results. They are advised to consult a hair-focused dermatologist for further evaluation.
PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.
The individual is experiencing hair loss due to insulin resistance (IR) and is seeking advice. They are currently using a keto diet, supplements, exercise, and plan to add metformin to their regimen.
An 18-year-old noticed hair thinning at 17, started finasteride 5 months ago, and saw shedding stop but no regrowth. They suspect male pattern baldness due to family history and are concerned about thinning on the back and sides, possibly due to inflammation.
PP405 cannot restore extracted hair follicles after a transplant as they are removed, not dormant. Combining verteporphin with wounding and PP405 is suggested but not confirmed effective.
The user shared progress after 9 months of using finasteride, minoxidil, and dermarolling for hair loss, despite some inconsistency in treatment. They are pleased with the results and plan to stop updating.
A 37-year-old male resolved scalp folliculitis by adopting a low-histamine diet and taking Vitamin A, Zinc, and Fish Oil, leading to better skin health and thicker hair. He warns about the potential toxicity of excessive Vitamin A intake.
The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.
Microneedling stimulates hair growth through stem cell activation during wound healing, not just increased blood flow. Other methods like showers or supplements don't replicate this effect.
PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.
Treatments for hair loss, specifically discussing the use of RU58841 and Pyrilutamide from Actifolic. The poster is inquiring about experiences with these products and results.
PP405 is a potential hair loss treatment showing promise, especially for men with severe balding. Some are hopeful it will be a game-changer for those who cannot tolerate finasteride or minoxidil, despite skepticism about the outcomes.
The conversation discusses progress with a hair loss treatment regimen that includes once daily topical Finasteride, Pyrilutamide, and WAY-316606. Specific treatments for hair loss are being shared and discussed.
A user's experience with hair loss and scalp inflammation, which was alleviated by using RU58841 along with finasteride and dutasteride. A theory of inflammation possibly being a cause of hairloss is also discussed.
User asks if stacking Alfatradiol and Fluridil is effective for hair loss. Alfatradiol is a weaker, topical 5ar inhibitor, while Fluridil is an anti-androgen preventing DHT binding to hair follicles.
The user had four DHI hair transplants from 2021 to 2025 and is concerned about the lack of hair thickening despite using treatments like finasteride and minoxidil. They are seeking advice on why these efforts aren't working.
The user experienced side effects from finasteride and is considering adding Alfatradiol or Fluridil to their regimen, which includes Minoxidil, dermarolling, and ketoconazole. Fluridil is noted to be more effective than Alfatradiol but less effective than finasteride, with mild side effects reported.
DUPA is considered more treatable than FAPD, as FAPD involves scarring that prevents hair regrowth. The user has started treatment with oral dutasteride and minoxidil, hoping for better results than previous treatments.
A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.
The user shared progress pictures after a year of treating hair loss with 5% minoxidil, then a combination of minoxidil/finasteride topical, and microneedling at 1.5mm bi-weekly. They plan to switch to oral finasteride and more frequent microneedling at a shallower depth while continuing the current regimen.